Urinary Tract Cancer Market Report 2026

The urinary tract cancer market size has grown rapidly in recent years. It will grow from $3.84 billion in 2025 to $4.56 billion in 2026 at a compound annual growth rate (CAGR) of 18.7%. The growth in the historic period can be attributed to increasing smoking-related cancer incidence, rising exposure to occupational carcinogens, improvements in cancer diagnostic capabilities, expansion of oncology treatment centers, growing awareness of urinary tract cancers.

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to increasing investments in personalized oncology treatments, rising adoption of immunotherapy approaches, expansion of AI-assisted diagnostic tools, growing focus on early screening programs, advancements in minimally invasive cancer surgery. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of advanced diagnostic imaging techniques, growing integration of precision oncology approaches, expansion of multimodal treatment strategies, enhanced focus on early cancer detection.

The rising prevalence of bladder cancer is expected to drive the expansion of the urinary tract cancer market. Bladder cancer involves the growth of malignant cells within the tissues of the urinary bladder, a hollow pelvic organ responsible for storing urine produced by the kidneys until it is expelled from the body. This increasing prevalence creates higher demand for diagnostic tools, screening techniques, and treatment options for patients with urinary tract cancer. For example, in January 2023, the American Cancer Society Inc., a US-based voluntary organization focused on cancer awareness, reported an estimated 168,560 cases of urinary system cancer in the United States, up 2.66% from 164,190 cases in 2022. Consequently, the rising incidence of bladder cancer is expected to support the growth of the urinary tract cancer market.

Leading companies in the urinary tract cancer market are emphasizing the development of next-generation therapies, such as antibody-drug conjugate (ADC) and immune-checkpoint inhibitor combination treatments, to provide more effective and personalized outcomes for urothelial carcinoma. These combination therapies integrate targeted cytotoxic ADCs with checkpoint inhibitors to simultaneously destroy tumor cells and enhance immune system activity, thereby improving response rates and survival in urinary tract cancers. For instance, in November 2025, Japan-based Astellas Pharma Inc. received U.S. FDA approval for PADCEV (enfortumab vedotin-ejfv) + KEYTRUDA (pembrolizumab) for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer. This regimen features a Nectin-4-directed ADC combined with PD-1 immune-checkpoint blockade and aims to reduce recurrence, progression, or death by approximately 60% compared to surgery alone. The therapy is on a regulatory path under the FDA’s Priority Review program, with a target action date of April 7, 2026.

In December 2023, Pfizer Inc. US-based acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer intends to strengthen its oncology portfolio by incorporating Seagen’s antibody-drug conjugate (ADC) technology and approved therapies to accelerate innovation in cancer treatment. Seagen Inc., a US biotechnology company, provides therapies for urinary tract cancer, particularly urothelial cancer, which is the most common form of bladder cancer.

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Seagen Inc., Exelixis Inc., UroGen Pharma Inc., Mersana Therapeutics, Spectrum Pharmaceuticals.

North America was the largest region in the urinary tract cancer market in 2025. The regions covered in the urinary tract cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the urinary tract cancer market by increasing costs of imported oncology drugs, diagnostic imaging equipment, surgical instruments, and radiation therapy systems. Cancer treatment centers in North America and Europe are most affected due to dependence on imported high-value medical technologies, while Asia-Pacific faces pricing pressure on pharmaceutical exports. These tariffs are increasing treatment costs and affecting therapy accessibility. However, they are also encouraging domestic pharmaceutical production, regional manufacturing of oncology equipment, and investment in localized cancer care infrastructure.

The urinary tract cancer market research report is one of a series of new reports that provides urinary tract cancer market statistics, including urinary tract cancer industry global market size, regional shares, competitors with a urinary tract cancer market share, detailed urinary tract cancer market segments, market trends and opportunities, and any further data you may need to thrive in the urinary tract cancer industry. This urinary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary tract cancer refers to malignant tumors that develop in the kidneys, bladder, ureters, or urethra, often presenting with symptoms such as blood in the urine and pain. Preventive measures, including quitting smoking, avoiding exposure to hazardous substances, and promptly treating urinary infections, can help reduce the risk of developing urinary tract cancer.

The main types of urinary tract cancer include bladder cancer, urethral cancer, ureteric cancer, and renal pelvic cancer. Bladder cancer involves the abnormal growth of cells in the bladder lining, directly affecting the urinary tract as the bladder is a key part of the urinary system. Treatment options include radical cystectomy, radiation therapy, and targeted therapy. Other treatments may involve chemotherapy, intravenous therapy, radiation therapy, and surgery. Diagnosis is carried out through cystoscopy, transurethral tumor resection, imaging tests, urine analyses, and other techniques. Treatment and diagnostic products are distributed through channels such as retail and online pharmacies.

The urinary tract cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgery and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary tract cancer market also includes sales of urinary catheters, cystoscopes, imaging equipment, urine cytology kits, pain relief medications and physical therapy devices which are used in providing diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.